iTeos Therapeutics ITOS 深 沪
等待开盘 02-03 09:30:00 美东时间
10.15
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 10.15
- 总市值 3.88亿
- 52周最高 17.63
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.80
- 委 比 0.00%
- 总股本 3827.38万
- 历史最高 52.43
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.80
- 每 手 1
- 风险率 1.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多【行业研究】创新药企业的信用风险特征研究：行业变革中的主体类别差异
中国创新药企业在政策支持、人口老龄化需求及BD模式崛起下快速发展，2025年1－9月中国创新药交易总额达937亿美元，全球占比近半。未来，随着大型跨国药企进入专...
2025-12-09 17:50
Kalaris Therapeutics Appoints Matthew Gall As New CFO To Support Growth And Clinical Expansion
Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew
2025-11-03 20:38
iTeos Therapeutics Completes Merger with Concentra Biosciences
The latest update is out from iTeos Therapeutics ( ($ITOS) ). On August 29, 202...
2025-08-29 21:25
GSK and iTeos Advance Immunotherapy Study for Lung Cancer
GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeut...
2025-08-16 00:25
Wells Fargo Maintains Equal-Weight on ITeos Therapeutics, Lowers Price Target to $11
Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:ITOS) with a Equal-Weight and lowers the price target from $12 to $11.
2025-08-07 22:48
ITeos Therapeutics Q2 EPS $(1.81) Misses $(0.95) Estimate
ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(0.95) by 89.73 percent. This is a 905.56 percent decrease over losses of $(0.18) per share
2025-08-06 20:32
Concentra Biosciences To Acquire iTeos For $10.047 In Cash Per Share Plus One Non-Transferable Contingent Value Right
iTeos Therapeutics, Inc. ("iTeos") (NASDAQ:ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire iTeos for $10.047 in cash per share of
2025-07-21 19:30
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
iTeos Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, under which Concentra will acquire iTeos for $10.047 per share of common stock, plus a contingent value right (CVR). The iTeos board unanimously approved the agreement, deeming it in the best interest of all stockholders. The transaction will commence with a tender offer by August 1, 2025, subject to conditions including shareholder majority and $475 mil...
2025-07-21 11:29
Tim Van Hauwermeiren Resigns from iTeos Board
iTeos Therapeutics ( ($ITOS) ) has shared an update. On June 1, 2025, Tim Van H...
2025-06-06 05:51
美股牛股 | 生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功
生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功；Joby Aviation大涨28%，获丰田汽车2.5亿美元战略投资>>
2025-05-29 19:18
